VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH MM 2021 | Elotuzumab, pomalidomide, and dexamethasone for advanced myeloma

Stefan Knop, MD, University Hospital of Würzburg, Würzburg, Germany, shares the findings of a retrospective study investigating the treatment of patients with multiple myeloma using elotuzumab, pomalidomide and dexamethasone. In this trial, 22 patients with advanced multiple myeloma were treated with this triplet combination. The study reported a median progression-free survival (PFS) of over seven months, with no difference between patients with standard- or high-risk disease, as defined by cytogenetics. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter